JPMorgan analyst Hardik Parikh assumed coverage of Pacira BioSciences with an Overweight rating and price target of $45, down from $80. Pacira is a pharmaceutical company that produces and sells non-opioid pain medications, the analyst tells investors in a research note. The firm says the company is set up well for growth starting in 2025, driven by several catalysts including regulatory, new indications, and manufacturing, that seem to be underappreciated by the Street.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCRX:
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Pacira price target lowered to $40 from $50 at Barclays
- Pacira Pharmaceuticals CFO Transition and Financial Update
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira reports Q4 EPS 89c, consensus 88c